Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Windlas Biotech Ltd. ( (IN:WINDLAS) ).
Windlas Biotech Limited announced the approval of the ‘Windlas Plan 2025’ by its shareholders, which includes a cap on the number of stock units that can be granted to employees. The Nomination and Remuneration Committee has made amendments to the plan to provide clarity on the number of units per employee per year, ensuring compliance with regulatory requirements without altering the approved limits. This move is aimed at maintaining transparency and aligning with stock exchange regulations, potentially impacting employee incentives and stakeholder confidence.
More about Windlas Biotech Ltd.
Windlas Biotech Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of pharmaceutical formulations. The company is known for its contract manufacturing services, catering to both domestic and international markets.
Average Trading Volume: 5,058
Technical Sentiment Signal: Strong Buy
Current Market Cap: 21.28B INR
See more insights into WINDLAS stock on TipRanks’ Stock Analysis page.